financetom
Business
financetom
/
Business
/
Eric and Trump Jr-backed manufacturing SPAC files for $300 million US IPO
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Eric and Trump Jr-backed manufacturing SPAC files for $300 million US IPO
Aug 4, 2025 8:37 AM

(Reuters) -New America Acquisition I Corp, a blank-check firm backed by Eric Trump and Donald Trump Jr., on Monday filed for an initial public offering of up to $300 million in the United States.

The move is the latest in a series of ventures by U.S. President Donald Trump's family, including a meme coin launched in January and World Liberty Financial, a crypto company partly owned by the president.

The Trump brothers have also expanded their holdings across golf courses, hotels, telecom and crypto miners, ventures which they say echo president's policies and agendas.

The special purpose acquisition company, a vehicle previously used by the family to launch firearms retailers and media firms, aims to merge with businesses headquartered or primarily operating in the U.S., it said in a filing.

The SPAC will "play a meaningful role in revitalizing domestic manufacturing, expanding innovation ecosystems, and strengthening critical supply chains", the filing added.

Since taking office, Trump has unraveled decades of trade relationships in pursuit of protectionist trade measures that he believes are necessary for national security.

Eric and Trump Jr. will both serve on the advisory board for New America, receiving a combined five million shares in the company.

Media veteran Kevin McGurn will lead the company. He declined a Reuters request for comment.

Dominari Securities President Kyle Wool, whose firm is an underwriter for this offering, is also on the board.

SPACs are shell companies that use their IPO proceeds to merge with a private company, thereby taking it public while avoiding the regulatory scrutiny of a traditional listing.

New America said it would offer 30 million units in its IPO priced at $10 each, aiming to list on the New York Stock Exchange.

D. Boral Capital is the other underwriter for the offering.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Theriva Biologics Shares Tumble After Pricing $2.5 Million Stock Offering
Theriva Biologics Shares Tumble After Pricing $2.5 Million Stock Offering
Oct 3, 2024
01:17 PM EDT, 09/27/2024 (MT Newswires) -- Theriva Biologics ( TOVX ) shares were nearly 26% lower in recent Friday trading after the company priced its $2.5 million public offering of its common shares and accompanying warrants. The company priced its offering of about 1.4 million shares and accompanying warrants to purchase as many shares at $1.75 apiece. The stock...
Willis Towers Watson Launches New China Client Division
Willis Towers Watson Launches New China Client Division
Oct 3, 2024
12:35 PM EDT, 09/27/2024 (MT Newswires) -- Willis Towers Watson ( WTW ) opened a new China client division as part of a broader Asia risk group. Jie Yan was appointed as division leader, the company said Friday in a statement. Price: 293.57, Change: +2.41, Percent Change: +0.83 ...
J.B. Hunt Transport Services Adds 20 Nikola Tre Fuel Cell Electric Vehicles
J.B. Hunt Transport Services Adds 20 Nikola Tre Fuel Cell Electric Vehicles
Oct 3, 2024
12:39 PM EDT, 09/27/2024 (MT Newswires) -- J.B. Hunt Transport Services (JBHT) said Friday that it is expanding its sustainability solutions for clients along the West Coast with the addition of 20 Nikola Tre fuel cell electric vehicles. Many of the new vehicles will support the company's intermodal operations in California and will be used for port and drayage transport,...
Estrella Says Lymphoma Patient Receiving EB103 Achieved Complete Response in Trial; Shares Up
Estrella Says Lymphoma Patient Receiving EB103 Achieved Complete Response in Trial; Shares Up
Oct 3, 2024
12:32 PM EDT, 09/27/2024 (MT Newswires) -- Estrella Immunopharma ( ESLA ) shares were up 20% in recent Friday trading after the company said a patient receiving its EB103 therapy achieved complete response in an ongoing trial of the medicine. The patient, the first to be enrolled in the phase 1/2 open-label Starlight-1 trial, was diagnosed with follicular lymphoma. One...
Copyright 2023-2026 - www.financetom.com All Rights Reserved